{"id":12060,"date":"2025-03-13T23:22:58","date_gmt":"2025-03-13T22:22:58","guid":{"rendered":"https:\/\/valintermed.com\/?p=12060"},"modified":"2025-03-13T23:22:58","modified_gmt":"2025-03-13T22:22:58","slug":"mielofibroz","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/myelofibroz\/","title":{"rendered":"Myelofibrosis"},"content":{"rendered":"
<\/div>\n

Myelofibrosis is a chronic disease caused by a disruption of the normal process of hematopoiesis in the bone marrow, which is characterized by the replacement of hematopoietic tissue with fibrous tissue. This leads to a decrease in the production of all types of formed elements of the blood, which is most often manifested by anemia, thrombocytopenia and leukopenia. This disease can be primary, occurring as an independent pathology, or secondary, developing against the background of other diseases, such as chronic myeloproliferative processes. The key aspect of myelofibrosis is the excessive formation of connective tissue, which significantly reduces the functional capacity of the bone marrow and can lead to various complications, including an enlarged spleen and liver, as well as increased vulnerability to infectious diseases.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n